Rituximab for membranous nephropathy and immune disease: less might be enough
- 2 December 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 5 (2) , 76-77
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosusAnnals of the Rheumatic Diseases, 2008
- Abbreviated dose rituximab for immune‐mediated hematological disordersAmerican Journal of Hematology, 2008
- Rituximab treatment of idiopathic membranous nephropathyKidney International, 2008
- Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2007
- Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic PurpuraAnnals of Internal Medicine, 2007
- Drug Insight: rituximab in renal disease and transplantationNature Clinical Practice Nephrology, 2006
- Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review.2004
- Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic reviewAmerican Journal of Kidney Diseases, 2004
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Rituximab for idiopathic membranous nephropathyThe Lancet, 2002